- Open
- 1.20
- High
- 1.23
- Low
- 1.17
- Close
- 1.17
- Change
- -0.05 (-4.17%)
- Volume
- 1,251,630
| 10 Sept 2026 | 07:00:05 | Welsh hospitals extend routine MT-RNR1 testing |
| 3 Sept 2026 | 07:00:05 | ShareSoc Investor Presentation Reminder |
| 1 Sept 2026 | 07:00:15 | Director/PDMR Notification |
| 21 Aug 2026 | 07:00:02 | Board Appointments |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
Genedrive plc develops and commercializes rapid pharmacogenetic testing solutions aimed at improving patient outcomes through personalized medicine. The company offers a near-patient testing platform that identifies genetic variants affecting drug response, enabling healthcare professionals to make informed treatment decisions quickly. Its primary products include the Genedrive® MT-RNR1 ID Kit, which helps prevent antibiotic-induced hearing loss in neonates, and the Genedrive® CYP2C19 ID Kit, designed for optimizing antiplatelet therapy in stroke patients. Genedrive operates primarily in the UK and collaborates with the National Health Service (NHS) to enhance clinical care pathways.
| 10 Sept 2026 | 07:00:05 | Welsh hospitals extend routine MT-RNR1 testing |
| 3 Sept 2026 | 07:00:05 | ShareSoc Investor Presentation Reminder |
| 1 Sept 2026 | 07:00:15 | Director/PDMR Notification |
| 21 Aug 2026 | 07:00:02 | Board Appointments |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
Genedrive plc develops and commercializes rapid pharmacogenetic testing solutions aimed at improving patient outcomes through personalized medicine. The company offers a near-patient testing platform that identifies genetic variants affecting drug response, enabling healthcare professionals to make informed treatment decisions quickly. Its primary products include the Genedrive® MT-RNR1 ID Kit, which helps prevent antibiotic-induced hearing loss in neonates, and the Genedrive® CYP2C19 ID Kit, designed for optimizing antiplatelet therapy in stroke patients. Genedrive operates primarily in the UK and collaborates with the National Health Service (NHS) to enhance clinical care pathways.
| 13 Aug 2026 |
| 07:00:04 |
| ShareSoc Investor Presentation |
| 3 Aug 2026 |
| genedrive shares rise 9% as UK guideline backs its hearing loss test |
| 10 Jul 2026 | AIM movers: Impax Asset Management asset improvement and Avingtrans raises cash for nuclear growth |
| 29 Jun 2026 | genedrive shares climb 8% on Thermo Fisher pharmacogenetic testing deal |
| 18 Jun 2026 | AIM movers: Seeing Machines extends contract and ex-dividends |
| 20 Jan 2026 | AIM movers: Underlying growth at Kromek and Eagle Eye beating expectations |
| 5 Dec 2025 | AIM movers: Anglesey Mining financial restructuring and new iodine plant for Iofina |
| 13 Aug 2026 |
| 07:00:04 |
| ShareSoc Investor Presentation |
| 3 Aug 2026 |
| genedrive shares rise 9% as UK guideline backs its hearing loss test |
| 10 Jul 2026 | AIM movers: Impax Asset Management asset improvement and Avingtrans raises cash for nuclear growth |
| 29 Jun 2026 | genedrive shares climb 8% on Thermo Fisher pharmacogenetic testing deal |
| 18 Jun 2026 | AIM movers: Seeing Machines extends contract and ex-dividends |
| 20 Jan 2026 | AIM movers: Underlying growth at Kromek and Eagle Eye beating expectations |
| 5 Dec 2025 | AIM movers: Anglesey Mining financial restructuring and new iodine plant for Iofina |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £303m | -0.1% | |
| £28m | +0.8% | |
| £19m | -0.4% | |
| £11m | -0.1% | |
| £11m | +0.3% | |
GDRGenedrive plc | £7m | +4.3% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £303m | -0.1% | |
| £28m | +0.8% | |
| £19m | -0.4% | |
| £11m | -0.1% | |
| £11m | +0.3% | |
GDRGenedrive plc | £7m | +4.3% |